R5 clade C SHIV strains with Tier 1 or 2 neutralization sensitivity: Tools to dissect env evolution and to develop AIDS vaccines in primate models

Nagadenahalli B. Siddappa, Jennifer D. Watkins, Klemens J. Wassermann, Ruijiang Song, Wendy Wang, Victor G. Kramer, Samir Lakhashe, Michael Santosuosso, Mark C. Poznansky, Francis J. Novembre, Francois Villinger, James G. Else, David C. Montefiori, Robert A. Rasmussen, Ruth M. Ruprecht

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current immunogens elicit antibodies that neutralize highly neutralization-sensitive (tier 1) HIV strains, most circulating HIVs exhibiting a less sensitive (tier 2) phenotype are not neutralized. Thus, both tier 1 and 2 viruses are needed for vaccine discovery in nonhuman primate models. Methodology/Principal Findings: We constructed a tier 1 simian-human immunodeficiency virus, SHIV-1157ipEL, by inserting an "early," recently transmitted HIV-C env into the SHIV-1157ipd3N4 backbone [1] encoding a "late" form of the same env, which had evolved in a SHIV-infected rhesus monkey (RM) with AIDS. SHIV-1157ipEL was rapidly passaged to yield SHIV-1157ipEL-p, which remained exclusively R5-tropic and had a tier 1 phenotype, in contrast to "late" SHIV-1157ipd3N4 (tier 2). After 5 weekly low-dose intrarectal exposures, SHIV-1157ipEL-p systemically infected 16 out of 17 RM with high peak viral RNA loads and depleted gut CD4+ T cells. SHIV-1157ipEL-p and SHIV-1157ipd3N4 env genes diverge mostly in V1/V2. Molecular modeling revealed a possible mechanism for the increased neutralization resistance of SHIV-1157ipd3N4 Env: V2 loops hindering access to the CD4 binding site, shown experimentally with nAb b12. Similar mutations have been linked to decreased neutralization sensitivity in HIV-C strains isolated from humans over time, indicating parallel HIV-C Env evolution in humans and RM. Conclusions/Significance: SHIV-1157ipEL-p, the first tier 1 R5 clade C SHIV, and SHIV-1157ipd3N4, its tier 2 counterpart, represent biologically relevant tools for anti-HIV-C vaccine development in primates.

Original languageEnglish (US)
Article numbere11689
JournalPloS one
Volume5
Issue number7
DOIs
StatePublished - Aug 17 2010

Fingerprint

AIDS Vaccines
Human immunodeficiency virus 1
neutralization
Primates
HIV-1
Vaccines
animal models
vaccines
Neutralizing Antibodies
Viruses
Macaca mulatta
Tropics
Molecular modeling
T-cells
Viral RNA
neutralizing antibodies
Genes
Binding Sites
phenotype
Antibodies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

R5 clade C SHIV strains with Tier 1 or 2 neutralization sensitivity : Tools to dissect env evolution and to develop AIDS vaccines in primate models. / Siddappa, Nagadenahalli B.; Watkins, Jennifer D.; Wassermann, Klemens J.; Song, Ruijiang; Wang, Wendy; Kramer, Victor G.; Lakhashe, Samir; Santosuosso, Michael; Poznansky, Mark C.; Novembre, Francis J.; Villinger, Francois; Else, James G.; Montefiori, David C.; Rasmussen, Robert A.; Ruprecht, Ruth M.

In: PloS one, Vol. 5, No. 7, e11689, 17.08.2010.

Research output: Contribution to journalArticle

Siddappa, NB, Watkins, JD, Wassermann, KJ, Song, R, Wang, W, Kramer, VG, Lakhashe, S, Santosuosso, M, Poznansky, MC, Novembre, FJ, Villinger, F, Else, JG, Montefiori, DC, Rasmussen, RA & Ruprecht, RM 2010, 'R5 clade C SHIV strains with Tier 1 or 2 neutralization sensitivity: Tools to dissect env evolution and to develop AIDS vaccines in primate models', PloS one, vol. 5, no. 7, e11689. https://doi.org/10.1371/journal.pone.0011689
Siddappa, Nagadenahalli B. ; Watkins, Jennifer D. ; Wassermann, Klemens J. ; Song, Ruijiang ; Wang, Wendy ; Kramer, Victor G. ; Lakhashe, Samir ; Santosuosso, Michael ; Poznansky, Mark C. ; Novembre, Francis J. ; Villinger, Francois ; Else, James G. ; Montefiori, David C. ; Rasmussen, Robert A. ; Ruprecht, Ruth M. / R5 clade C SHIV strains with Tier 1 or 2 neutralization sensitivity : Tools to dissect env evolution and to develop AIDS vaccines in primate models. In: PloS one. 2010 ; Vol. 5, No. 7.
@article{8dbf4f2785cb49f3ae80dc518a2bdc51,
title = "R5 clade C SHIV strains with Tier 1 or 2 neutralization sensitivity: Tools to dissect env evolution and to develop AIDS vaccines in primate models",
abstract = "Background: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current immunogens elicit antibodies that neutralize highly neutralization-sensitive (tier 1) HIV strains, most circulating HIVs exhibiting a less sensitive (tier 2) phenotype are not neutralized. Thus, both tier 1 and 2 viruses are needed for vaccine discovery in nonhuman primate models. Methodology/Principal Findings: We constructed a tier 1 simian-human immunodeficiency virus, SHIV-1157ipEL, by inserting an {"}early,{"} recently transmitted HIV-C env into the SHIV-1157ipd3N4 backbone [1] encoding a {"}late{"} form of the same env, which had evolved in a SHIV-infected rhesus monkey (RM) with AIDS. SHIV-1157ipEL was rapidly passaged to yield SHIV-1157ipEL-p, which remained exclusively R5-tropic and had a tier 1 phenotype, in contrast to {"}late{"} SHIV-1157ipd3N4 (tier 2). After 5 weekly low-dose intrarectal exposures, SHIV-1157ipEL-p systemically infected 16 out of 17 RM with high peak viral RNA loads and depleted gut CD4+ T cells. SHIV-1157ipEL-p and SHIV-1157ipd3N4 env genes diverge mostly in V1/V2. Molecular modeling revealed a possible mechanism for the increased neutralization resistance of SHIV-1157ipd3N4 Env: V2 loops hindering access to the CD4 binding site, shown experimentally with nAb b12. Similar mutations have been linked to decreased neutralization sensitivity in HIV-C strains isolated from humans over time, indicating parallel HIV-C Env evolution in humans and RM. Conclusions/Significance: SHIV-1157ipEL-p, the first tier 1 R5 clade C SHIV, and SHIV-1157ipd3N4, its tier 2 counterpart, represent biologically relevant tools for anti-HIV-C vaccine development in primates.",
author = "Siddappa, {Nagadenahalli B.} and Watkins, {Jennifer D.} and Wassermann, {Klemens J.} and Ruijiang Song and Wendy Wang and Kramer, {Victor G.} and Samir Lakhashe and Michael Santosuosso and Poznansky, {Mark C.} and Novembre, {Francis J.} and Francois Villinger and Else, {James G.} and Montefiori, {David C.} and Rasmussen, {Robert A.} and Ruprecht, {Ruth M.}",
year = "2010",
month = "8",
day = "17",
doi = "10.1371/journal.pone.0011689",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - R5 clade C SHIV strains with Tier 1 or 2 neutralization sensitivity

T2 - Tools to dissect env evolution and to develop AIDS vaccines in primate models

AU - Siddappa, Nagadenahalli B.

AU - Watkins, Jennifer D.

AU - Wassermann, Klemens J.

AU - Song, Ruijiang

AU - Wang, Wendy

AU - Kramer, Victor G.

AU - Lakhashe, Samir

AU - Santosuosso, Michael

AU - Poznansky, Mark C.

AU - Novembre, Francis J.

AU - Villinger, Francois

AU - Else, James G.

AU - Montefiori, David C.

AU - Rasmussen, Robert A.

AU - Ruprecht, Ruth M.

PY - 2010/8/17

Y1 - 2010/8/17

N2 - Background: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current immunogens elicit antibodies that neutralize highly neutralization-sensitive (tier 1) HIV strains, most circulating HIVs exhibiting a less sensitive (tier 2) phenotype are not neutralized. Thus, both tier 1 and 2 viruses are needed for vaccine discovery in nonhuman primate models. Methodology/Principal Findings: We constructed a tier 1 simian-human immunodeficiency virus, SHIV-1157ipEL, by inserting an "early," recently transmitted HIV-C env into the SHIV-1157ipd3N4 backbone [1] encoding a "late" form of the same env, which had evolved in a SHIV-infected rhesus monkey (RM) with AIDS. SHIV-1157ipEL was rapidly passaged to yield SHIV-1157ipEL-p, which remained exclusively R5-tropic and had a tier 1 phenotype, in contrast to "late" SHIV-1157ipd3N4 (tier 2). After 5 weekly low-dose intrarectal exposures, SHIV-1157ipEL-p systemically infected 16 out of 17 RM with high peak viral RNA loads and depleted gut CD4+ T cells. SHIV-1157ipEL-p and SHIV-1157ipd3N4 env genes diverge mostly in V1/V2. Molecular modeling revealed a possible mechanism for the increased neutralization resistance of SHIV-1157ipd3N4 Env: V2 loops hindering access to the CD4 binding site, shown experimentally with nAb b12. Similar mutations have been linked to decreased neutralization sensitivity in HIV-C strains isolated from humans over time, indicating parallel HIV-C Env evolution in humans and RM. Conclusions/Significance: SHIV-1157ipEL-p, the first tier 1 R5 clade C SHIV, and SHIV-1157ipd3N4, its tier 2 counterpart, represent biologically relevant tools for anti-HIV-C vaccine development in primates.

AB - Background: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current immunogens elicit antibodies that neutralize highly neutralization-sensitive (tier 1) HIV strains, most circulating HIVs exhibiting a less sensitive (tier 2) phenotype are not neutralized. Thus, both tier 1 and 2 viruses are needed for vaccine discovery in nonhuman primate models. Methodology/Principal Findings: We constructed a tier 1 simian-human immunodeficiency virus, SHIV-1157ipEL, by inserting an "early," recently transmitted HIV-C env into the SHIV-1157ipd3N4 backbone [1] encoding a "late" form of the same env, which had evolved in a SHIV-infected rhesus monkey (RM) with AIDS. SHIV-1157ipEL was rapidly passaged to yield SHIV-1157ipEL-p, which remained exclusively R5-tropic and had a tier 1 phenotype, in contrast to "late" SHIV-1157ipd3N4 (tier 2). After 5 weekly low-dose intrarectal exposures, SHIV-1157ipEL-p systemically infected 16 out of 17 RM with high peak viral RNA loads and depleted gut CD4+ T cells. SHIV-1157ipEL-p and SHIV-1157ipd3N4 env genes diverge mostly in V1/V2. Molecular modeling revealed a possible mechanism for the increased neutralization resistance of SHIV-1157ipd3N4 Env: V2 loops hindering access to the CD4 binding site, shown experimentally with nAb b12. Similar mutations have been linked to decreased neutralization sensitivity in HIV-C strains isolated from humans over time, indicating parallel HIV-C Env evolution in humans and RM. Conclusions/Significance: SHIV-1157ipEL-p, the first tier 1 R5 clade C SHIV, and SHIV-1157ipd3N4, its tier 2 counterpart, represent biologically relevant tools for anti-HIV-C vaccine development in primates.

UR - http://www.scopus.com/inward/record.url?scp=77955490068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955490068&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0011689

DO - 10.1371/journal.pone.0011689

M3 - Article

C2 - 20657739

AN - SCOPUS:77955490068

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e11689

ER -